Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Surg Pathol. 2009 Aug;33(8):1220-4. doi: 10.1097/PAS.0b013e3181a24354.

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.

Author information

  • 1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.

Abstract

A 2-tier grading system based on nuclear grade divides ovarian serous carcinomas into low (nuclear grade 1) and high grade (nuclear grade 3). In most instances the separation is straightforward but at times, the morphologic distinction between them can be difficult. We studied 11 ovarian serous carcinomas with features that were "intermediate" (nuclear grade 2) between low and high grade. All the cases were high staged and had a poor clinical outcome. None of the tumors showed mutations in KRAS, BRAF, and ERBB2 genes that characterize most low-grade serous carcinomas. In contrast, 10 (90.9%) of 11 cases contained nonsynonymous TP53 mutations characteristic of high-grade serous carcinomas. In summary, the molecular genetic profile and behavior of serous carcinomas with grade 2 nuclei are virtually the same as those of serous carcinomas with grade 3 nuclei, supporting the use of the 2-tier grading system for classifying ovarian serous carcinomas.

PMID:
19461510
[PubMed - indexed for MEDLINE]
PMCID:
PMC2716424
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1
Fig. 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk